| Entries |
| Document | Title | Date |
|---|
| 20090149445 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS - The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: | 06-11-2009 |
| 20090176759 | LEUKEMIC STEM CELL ABLATION - A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia. | 07-09-2009 |
| 20090270368 | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof - The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease. | 10-29-2009 |
| 20090275561 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 11-05-2009 |
| 20100029616 | UROTENSIN II RECEPTOR ANTAGONISTS - The present invention is directed to compounds of formula (I) | 02-04-2010 |
| 20100216773 | PHENANTHROINDOLIZIDINE ANALOGUES - Treatment of coronavirus infection with phenanthroindolizidine analogues. | 08-26-2010 |
| 20100216774 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 08-26-2010 |
| 20110009388 | Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine - The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments. | 01-13-2011 |
| 20110092486 | IH CHANNEL INHIBITORS FOR THE PROMOTION OF WAKEFULNESS - The present invention relates to use of an I | 04-21-2011 |
| 20120058991 | Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine - The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments. | 03-08-2012 |
| 20120115847 | Compounds for the Treatment of Hepatitis C - The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 05-10-2012 |
| 20130102589 | Novel Compound for the Treatment of Hepatitis C - The present invention provides (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 04-25-2013 |
| 20130210806 | TRICYCLIC INDOLE DERIVATIVES USEFUL ENDOTHELIAL LIPASE INHIBITORS - The present invention is directed to tricyclic indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders. | 08-15-2013 |
| 20140171416 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention provides novel | 06-19-2014 |
| 20140206669 | AMINATED DERIVATIVE OF HOMOHARRINGTONINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry and specifically relates to novel aminated homoharringtonine derivatives of formula (I) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. | 07-24-2014 |
| 20140235617 | Combinations of Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations. | 08-21-2014 |
| 20140303147 | ACYLATED DERIVATIVE OF HOMOHARRINGTONINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and relates to novel homoharringtonine acylated derivatives of formula (I) and formula (II) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. | 10-09-2014 |
| 20140343039 | PROCESS FOR PREPARING CEPHALOTAXINE ESTERS - There is provided a process for preparing cephalotaxine esters corresponding to the following general formula I, which comprises the cephalotaxine backbone, and that can be written as C(R | 11-20-2014 |
| 20150335655 | Combinations of Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations. | 11-26-2015 |
